# A Study to Assess the Effects of PT001 and PT005 MDI on Specific Image Based Parameters in Subjects With Moderate to Severe COPD

> **NCT02937584** · PHASE3 · COMPLETED · sponsor: **Pearl Therapeutics, Inc.** · enrollment: 23 (actual)

## Conditions studied

- COPD, Chronic Obstructive Pulmonary Disease

## Interventions

- **DRUG:** GP MDI (PT001) 14.4 μg
- **DRUG:** FF MDI (PT005) 9.6 μg

## Key facts

- **NCT ID:** NCT02937584
- **Lead sponsor:** Pearl Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-12-29
- **Primary completion:** 2018-05-28
- **Final completion:** 2018-05-28
- **Target enrollment:** 23 (ACTUAL)
- **Last updated:** 2019-07-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02937584

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02937584, "A Study to Assess the Effects of PT001 and PT005 MDI on Specific Image Based Parameters in Subjects With Moderate to Severe COPD". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02937584. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*